Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis

Investigational Site Number : 1240019, Calgary

Investigational Site Number : 1240021, Calgary

Investigational Site Number : 1240009, Edmonton

Investigational Site Number : 1240007, Edmonton

Investigational Site Number : 1240028, Nanaimo

Investigational Site Number : 1240010, Surrey

Investigational Site Number : 1240029, Winnipeg

Investigational Site Number : 1240026, Fredericton

Investigational Site Number : 1240020, Halifax

Investigational Site Number : 1240002, Ajax

Investigational Site Number : 1240024, Barrie

Investigational Site Number : 1240031, Cobourg

Investigational Site Number : 1240011, Etobicoke

Investigational Site Number : 1240016, London

Investigational Site Number : 1240025, Newmarket

Investigational Site Number : 1240008, Peterborough

Investigational Site Number : 1240005, Richmond Hill

Investigational Site Number : 1240033, Toronto

Investigational Site Number : 1240030, Toronto

Investigational Site Number : 1240014, Toronto

Investigational Site Number : 1240018, Waterloo

Investigational Site Number : 1240034, Whitby

Investigational Site Number : 1240012, Montreal

Investigational Site Number : 1240017, Montreal

Investigational Site Number : 1240006, Pointe-Claire

Investigational Site Number : 1240013, Québec

Investigational Site Number : 1240023, Saint-Jean-sur-Richelieu

Investigational Site Number : 1240003, Regina

Investigational Site Number : 1240027, Saskatoon